Effect of Methamphetamine on Residual Latent HIV Disease Study

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 11, 2023

Study Completion Date

January 11, 2023

Conditions
HIV-1-infectionMethamphetamine-dependence
Interventions
DRUG

Oral Methamphetamine

An initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.

OTHER

Placebo oral capsule

One placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.

Trial Locations (1)

94110

San Francisco General Hospital, San Francisco

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of California, San Francisco

OTHER

NCT03825536 - Effect of Methamphetamine on Residual Latent HIV Disease Study | Biotech Hunter | Biotech Hunter